

LEADING REGENERATION

Geistlich  
Biomaterials

# Geistlich Bio-Oss Pen<sup>®</sup>

Treatment made simple.  
For you and your patient.

Hydrate.  
Change Tips.  
Apply.

Geistlich Bio-Oss<sup>®</sup>  
in a user-friendly  
applicator<sup>1</sup>





# Ready to use in just a few simple steps

## For you and your patient.

If you have a patient with a bone defect that is difficult to access, or who has limited mouth opening, treatment using Guided Bone Regeneration can seem impractical, even when it is the recommended course. But our latest solution makes it easy.

The Geistlich Bio-Oss Pen® **simplifies** the **treatment** process and **avoids painful bone harvesting**.<sup>2,10</sup> Sounds good? We thought so.

The **Geistlich Bio-Oss Pen®** is a pre-filled syringe containing Geistlich Bio-Oss® granules – the market-leading natural bone substitute for bone grafting that is chemically and structurally comparable to human bone mineral.<sup>1,3</sup> The Geistlich Bio-Oss® biofunctionality promotes vascularisation and the formation of new bone.<sup>3</sup>

**The Geistlich Bio-Oss Pen® is used by leading clinicians because our innovative applicator:<sup>2</sup>**

- > Is convenient and easy to use<sup>2</sup>
- > Ensures the correct consistency of Geistlich Bio-Oss® granules<sup>2</sup>
- > Makes it easier to access posterior regions of the mouth<sup>2</sup>
- > Reduces spillage and residual granule waste<sup>2</sup>


# Keep your treatment options open

## Your choice.

The Geistlich Bio-Oss Pen® is available pre-filled with either small (0.25–1 mm) or large (1–2 mm) Geistlich Bio-Oss® granules.

Our recommendation is to use Geistlich Bio-Oss Pen® with **small granules** for small defects and autogenous grafts contouring. Geistlich Bio-Oss Pen® with **large granules** for larger augmentations and sinus floor elevation.

**Achieve the same clinical performance with either small or large granules<sup>5,6</sup>**



**15 million patients treated<sup>4</sup>**

Geistlich Bio-Oss® is the most frequently used bone substitute in oral and maxillofacial surgery worldwide and has been successfully used to treat more than 15 million patients.<sup>1,4</sup>



SCAN TO FIND OUT MORE ABOUT GEISTLICH BIO-OSS®

**High implant survival rate with Geistlich Bio-Gide®<sup>8,9</sup>**

The combination of Geistlich Bio-Oss® and Geistlich Bio-Gide® in Guided Bone Regeneration is considered the standard modern treatment, and is used in a wide range of clinical procedures.<sup>7</sup>

The slow resorption rate of Geistlich Bio-Oss® alongside the protective functionality of Geistlich Bio-Gide® promotes the long-term clinical volume stability of the augmented bone and ensures high implant survival rates.<sup>8,9</sup>



SCAN TO FIND OUT MORE ABOUT GEISTLICH BIO-GIDE®

**Hydrate.  
Change Tips.  
Apply.**

The Geistlich Bio-Oss Pen® is ready to use in just three simple steps, and 9 out of 10 dentists find it easy to handle.<sup>2</sup>



SCAN TO WATCH THE INSTRUCTION VIDEO FOR THE GEISTLICH BIO-OSS PEN®







More details about our distribution partners:  
[www.geistlich-biomaterials.com](http://www.geistlich-biomaterials.com)

**Manufacturer**

Geistlich Pharma AG  
Business Unit Biomaterials  
Bahnhofstrasse 40  
6110 Wolhusen, Switzerland  
Phone +41 41 492 55 55  
Fax +41 41 492 56 39  
[www.geistlich-biomaterials.com](http://www.geistlich-biomaterials.com)

**Affiliate Australia and New Zealand**

Geistlich Pharma Australia Pty Ltd.  
The Zenith – Tower A  
Level 21, Suite 21.01  
821 Pacific Highway  
NSW 2067 Chatswood, Australia  
Phone +61 1800 776 326  
Fax +61 1800 709 698  
[info@geistlich.com.au](mailto:info@geistlich.com.au)  
[www.geistlich.com.au](http://www.geistlich.com.au)

**Affiliate Great Britain and Ireland**

Geistlich Sons Limited  
1st Floor, Thorley House  
Bailey Lane  
Manchester Airport  
Manchester M90 4AB, Great Britain  
Phone +44 161 490 2038  
Fax +44 161 498 6988  
[info@geistlich.co.uk](mailto:info@geistlich.co.uk)  
[www.geistlich.co.uk](http://www.geistlich.co.uk)

**Affiliate North America**

Geistlich Pharma North America Inc.  
902 Carnegie Center, Suite 360  
Princeton, NJ 08540 USA  
Phone +1 855 799 5500  
[info@geistlich-na.com](mailto:info@geistlich-na.com)  
[www.geistlich-na.com](http://www.geistlich-na.com)

**Distribution Canada**

HANSAmEd Ltd.  
2830 Argentia Road  
Unit 5–8  
L5N 8G4 Mississauga, Canada  
Phone +1 800 363 2876  
Fax +1 800 863 3213  
[orders@hansamed.net](mailto:orders@hansamed.net)  
[www.hansamed.net](http://www.hansamed.net)

Discover our easy-to-use solution

# Start your journey now.

Nine out of 10 clinicians find the Geistlich Bio-Oss Pen® easy to use.<sup>2</sup>  
Experience it for yourself!



The Geistlich Bio-Oss Pen® offers **enhanced handling**.<sup>2</sup> Start your journey towards straight forward treatments now.

## BUY

Can't wait to treat more patients, more easily?



VISIT OUR  
E-SHOP NOW!

## TRY

Want to find out just how easy the Geistlich Bio-Oss Pen® is to use before purchasing?



BOOK A PRODUCT  
DEMO WITH OUR  
PRODUCT SPECIALISTS!

## LEARN

Are you interested in enhancing your surgical skills in the area of Guided Bone Regeneration and learning new techniques in different treatment areas?



SIGN UP TO ONE OF OUR  
COURSES TAUGHT BY  
WORLD-LEADING EXPERTS!

1 Market report suite for dental bone graft substitutes and other biomaterials. iData Research Inc. Europe 2019, South Korea 2018, US 2019, India 2018, Japan 2018, Australia 2018, China 2018 (Market Research).  
2 Geistlich Pharma AG practice test, Nov 2011. Data on file (Wolhusen, Switzerland).  
3 Galindo-Moreno P et al.: Clin Oral Implants Res 2010; 21 (2), 221-7.  
4 Data on file. Based on the number of units currently sold. (Wolhusen, Switzerland).  
5 Chackartchi T et al.: Clin Oral Impl. Res 2011; 22, 473–480  
6 dos Anjos TLM, et al.: Int J Oral Maxillofac Surg 2016; 45 (12),1556-1563  
7 Buser D et al.: J Dent Res 2013; 92 (12 Suppl), 1765-82S  
8 Jung RE et al.: Clin Oral Implants Res 2013; 24 (10), 1065-73.  
9 Mordenfeld A et al.: Clin Oral Implants Res 2010; 21 (9), 961-70.  
10 Orsini G et al.: Oral Dis 2007; 13 (6), 586-93.